Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OKSI is a nutraceutical combination supplement consisting of extracts from mangosteen (*Garcinia mangostana*) peel and tomato (*Solanum lycopersicum*). Developed by researchers at Universitas Negeri Semarang (UNNES), it is specifically designed to mitigate exercise-induced oxidative stress, particularly in sedentary individuals. The formulation leverages the antioxidant properties of xanthones (such as alpha-mangostin) found in mangosteen and lycopene found in tomatoes. These bioactive compounds function by scavenging reactive oxygen species (ROS) and enhancing the activity of endogenous antioxidant enzymes, such as superoxide dismutase (SOD). Clinical evaluation in randomized, double-blind, placebo-controlled trials has demonstrated its ability to reduce markers of lipid peroxidation, such as malondialdehyde (MDA), following physical exertion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on OKSI.